HSBC/CALL/PFIZER INC/60/0.1/19.06.24 Share Price

Warrant

DE000HG4B4P1

Real-time BOERSE MUENCHEN 07:07:02 28/05/2024 pm IST
0.011 EUR 0.00% Intraday chart for HSBC/CALL/PFIZER INC/60/0.1/19.06.24
Date Price Change
28/24/28 0.011 0.00%
27/24/27 0.011 0.00%
24/24/24 0.011 0.00%
23/24/23 0.011 0.00%
22/24/22 0.011 0.00%

Real-time BOERSE MUENCHEN

Last update May 28, 2024 at 07:07 pm IST

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying PFIZER, INC.
Issuer HSBC
WKN HG4B4P
ISINDE000HG4B4P1
Date issued 23/06/2022
Strike 60 $
Maturity 19/06/2024 (22 Days)
Parity 10 : 1
Emission price 0.39
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.62
Lowest since issue 0.011
Delta0.03x
Omega 7.979
Premium108.17x
Gearing241.32x
Moneyness 0.4813
Difference Strike 31.62 $
Difference Strike %+52.69%
Spread 0.02
Spread %95.24%
Theoretical value 0.0110
Implied Volatility 148.47 %
Total Loss Probability 98.62 %
Intrinsic value 0.000000
Present value 0.0110
Break even 60.12 €
Theta-0.01x
Vega0x
Rho0x

Company Profile

Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (72.8%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (13.8%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (12.1%); - other (1.3%). At the end of 2022, the group had more than 35 manufacturing sites worldwide. Net sales are distributed geographically as follows: the United States (42.3%), Europe (21.9%) and other (35.8%).
Sector
-
More about the company

Ratings for Pfizer, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Pfizer, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
28.88 USD
Average target price
31.92 USD
Spread / Average Target
+10.51%
Consensus